Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tempest Therapeutics Inc.

9.92
+0.07000.71%
Post-market: 9.920.00000.00%16:42 EDT
Volume:25.57K
Turnover:253.83K
Market Cap:44.05M
PE:-0.51
High:10.42
Open:10.03
Low:9.73
Close:9.85
52wk High:20.67
52wk Low:5.35
Shares:4.44M
Float Shares:4.16M
Volume Ratio:0.29
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-19.4955
EPS(LYR):-19.4955
ROE:-322.57%
ROA:-81.34%
PB:4.50
PE(LYR):-0.51

Loading ...

Tempest Therapeutics Q2 EPS $(2.07) Beats $(3.23) Estimate

Benzinga
·
Aug 12

Tempest Therapeutics posts smaller-than-expected Q2 net loss

Reuters
·
Aug 12

Tempest Therapeutics Reports Narrowed Q2 2025 Net Loss of $7.9M, EPS at $2.07, Down from $5.52 in 2024; Cash Reserves Halved to $14.3M

Reuters
·
Aug 12

Tempest Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview

Reuters
·
Aug 09

Tempest Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview

Reuters
·
Aug 05

Tempest Therapeutics Receives Green Light from China's NMPA for Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC

Reuters
·
Jun 30

Tempest Therapeutics Inc. Files Prospectus for $6.25 Million Direct Offering to Fund Strategic Initiatives and Operations

Reuters
·
Jun 13

Tempest Therapeutics Announces $4.6 Million Registered Direct Offering of Common Stock to Institutional Investor

Reuters
·
Jun 11

BRIEF-Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025 - SEC Filing

Reuters
·
Jun 11

Tempest Therapeutics Suspends Prospectus Supplement, Halts Securities Sales Under Jefferies Agreement

Reuters
·
Jun 11

Top Premarket Gainers

MT Newswires Live
·
Jun 09

24H|Chinese ADRs Gain Ahead of US-China Trade Talks; AppLovin, Robinhood Dip Missing S&P 500 Inclusion

Tiger Newspress
·
Jun 09

Stocks to Watch: Children's Place, Tempest Therapeutics

Dow Jones
·
Jun 07

Tempest Therapeutics Inc. Announces Management Transition to Consulting Roles for CEO, CFO, and CMO

Reuters
·
Jun 07

Tempest Therapeutics Secures Orphan Drug Designation from European Medicines Agency for Amezalpat in Hepatocellular Carcinoma Treatment

Reuters
·
Jun 05

Tempest Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Tempest Therapeutics Inc expected to post a loss of $3.51 a share - Earnings Preview

Reuters
·
May 14

Tempest Therapeutics Reports Q1 2025 Results: Net Loss Widens to $10.9M, EPS at $3.16

Reuters
·
May 14

Tempest Therapeutics Inc expected to post a loss of $3.29 a share - Earnings Preview

Reuters
·
May 05

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

GlobeNewswire
·
Apr 29